Department of Obstetrics/Gynecology and Reproductive Medicine, UniKiD Center for Reproductive Medicine (UniKiD), Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine University, Universitätsstraße 1, 40225, Duesseldorf, Germany.
Global Medical Affairs Fertility, Merck Healthcare KGaA, Frankfurter Strasse 250, Darmstadt, 64293, Germany.
Best Pract Res Clin Obstet Gynaecol. 2023 Jul;89:102350. doi: 10.1016/j.bpobgyn.2023.102350. Epub 2023 May 11.
This non-interventional study compared the effectiveness of recombinant human follicle-stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) (2:1 ratio) versus r-hFSH alone for ovarian stimulation (OS) during assisted reproductive technology treatment in women aged 35-40 years, using real-world data from the Deutsches IVF-Register (D·I·R). Numerically higher clinical pregnancy (29.8% [95% CI 28.2, 31.6] vs. 27.8% [26.5, 29.2]) and live birth (20.3% [18.7, 21.8] vs. 18.0% [16.6, 19.4]) rates were observed with r-hFSH:r-hLH versus r-hFSH alone. The treatment effect was consistently higher for r-hFSH:r-hLH compared with r-hFSH alone in terms of clinical pregnancy (relative risk [RR] 1.16 [1.05, 1.26]) and live birth (RR 1.16 [1.02, 1.31]) in a post-hoc analysis of women with 5-14 oocytes retrieved (used as a surrogate for normal ovarian reserve), highlighting the potential benefits of r-hFSH:r-hLH for OS in women aged 35-40 years with normal ovarian reserve.
本非干预性研究比较了在辅助生殖技术治疗中，重组人卵泡刺激素（r-hFSH）和重组人黄体生成素（r-hLH）（2:1 比例）与单独使用 r-hFSH 对卵巢刺激（OS）的效果，使用了来自德国 IVF 注册（D·I·R）的真实世界数据。在一项对获得 5-14 个卵母细胞（作为正常卵巢储备的替代指标）的女性进行的事后分析中，r-hFSH:r-hLH 组的临床妊娠率（29.8%[95%CI 28.2, 31.6]vs. 27.8%[26.5, 29.2]）和活产率（20.3%[18.7, 21.8]vs. 18.0%[16.6, 19.4]）均高于单独使用 r-hFSH 组。r-hFSH:r-hLH 组的临床妊娠（相对风险 [RR] 1.16[1.05, 1.26]）和活产（RR 1.16[1.02, 1.31]）的治疗效果均高于单独使用 r-hFSH 组，这表明 r-hFSH:r-hLH 对具有正常卵巢储备的 35-40 岁女性的 OS 可能具有潜在益处。
